Takeaway
The results from this study suggest that central nervous system (CNS) B cells could be a treatment target in those with leucine-rich, glioma-inactivated 1 (LGI1) antibody encephalitis.
Why this matters
Little is known about the cerebrospinal fluid (CSF) B-cell response against LGI1 in the periphery or CSF, and given that LGI1 antibody encephalitis often results in neurological and cognitive impairment, this information is greatly sought.
With this information, further therapeutic targets can be identified and tested, thus giving rise to new, more specific, treatments.